Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • KX2-391 dihydrochloride: Dual Src and Tubulin Inhibitor f...

    2026-02-20

    KX2-391 dihydrochloride: A Dual-Mechanism Tool for Targeted Cancer, Antiviral, and Neurotoxin Research

    Principle and Setup: Unlocking the Power of a Dual Src and Tubulin Inhibitor

    KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) is a unique small-molecule inhibitor characterized by its dual action: potent, non-ATP-competitive inhibition of Src kinase and targeted disruption of tubulin polymerization. This dual mechanism underpins its broad utility as an anticancer agent targeting Src kinase, a tubulin polymerization inhibitor, and an HBV transcription inhibitor, while also providing activity against botulinum neurotoxin A (BoNT/A).

    Mechanistically, KX2-391 dihydrochloride binds the substrate recognition site of Src kinase, exhibiting IC50 values of 23 nM in NIH3T3/c-Src527F cells and 39 nM in SYF/c-Src527F cells. It also interacts with a novel binding pocket on the α-β tubulin heterodimer, requiring ≥80 nM for tubulin cytoskeleton disruption in cellular contexts. The compound’s multi-targeted approach enables researchers to probe the Src kinase signaling pathway, tubulin polymerization pathway, HBV replication pathway, and caspase signaling pathway with a single agent.

    For optimal solubilization, KX2-391 dihydrochloride is highly soluble in DMSO (≥25.2 mg/mL) and ethanol (≥48.8 mg/mL with gentle warming), but insoluble in water. It is supplied as a solid and should be stored at -20°C to maintain stability.

    Step-by-Step Workflow and Protocol Enhancements

    1. In Vitro Cancer Cell Assays Targeting Src and Tubulin Pathways

    • Preparation: Dissolve KX2-391 dihydrochloride in DMSO to generate a 10 mM stock solution. Ensure complete dissolution with mild vortexing or brief sonication. Store aliquots at -20°C to prevent freeze-thaw cycles.
    • Cell Seeding: Plate cancer cell lines (e.g., NIH3T3/c-Src527F, MDA-MB-231) at optimal densities 24 hours prior to treatment to ensure logarithmic growth phase.
    • Treatment: Add KX2-391 dihydrochloride at concentrations ranging from 0.013 to 10 μM. Include DMSO-only controls and, where relevant, positive controls such as paclitaxel for tubulin studies or dasatinib for Src inhibition.
    • Assays:
      • Cell Viability: Use MTT, CellTiter-Glo, or AlamarBlue assays after 24–72 hours of treatment.
      • Tubulin Polymerization: Employ immunofluorescence microscopy or cell-based ELISA for α-tubulin to visualize cytoskeletal disruption at ≥80 nM.
      • Src Pathway Analysis: Western blot for phosphorylated Src (Y416) and downstream effectors (FAK, p130Cas).

    2. Antiviral Workflows: HBV Transcription Inhibition

    • Cell Model: Use HepG2-NTCP or PXB cells, which support productive HBV infection and transcription.
    • HBV Reporter System: Transfect with recombinant HBV/NanoLuc or infect with HBV, as described in Harada et al., 2017.
    • Treatment: Apply KX2-391 dihydrochloride at 0.1–5 μM. The EC50 for inhibition of HBV transcription is 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells, indicating potent activity within physiologically relevant ranges.
    • Readout: Measure NanoLuc luciferase activity and HBV RNA levels after 3–5 days to quantify transcriptional inhibition.

    3. BoNT/A Inhibition and Neuroprotection Studies

    • In Vitro Assays: Use neuronal cell lines or SNAP-25 cleavage reporter systems.
    • Treatment: Incubate cells with 10–40 μM KX2-391 dihydrochloride prior to BoNT/A exposure. Assess inhibition of SNAP-25 cleavage via immunoblotting.

    4. In Vivo Models

    • Cancer Xenograft Models: Oral dosing in mice at 5–15 mg/kg once or twice daily supports robust plasma concentrations with minimal peripheral neuropathy.
    • HBV Models: In chimpanzees, 1 mg/kg twice daily achieves anti-HBV activity.

    For all in vivo applications, ensure protocols comply with ethical guidelines and optimize formulation for bioavailability (e.g., DMSO/PEG400/Saline blends).

    Advanced Applications and Comparative Advantages

    KX2-391 dihydrochloride’s dual mechanism provides unique advantages over single-target agents in both basic and translational research:

    • Pathway Dissection: Its capacity as a Src kinase inhibitor and tubulin polymerization inhibitor enables simultaneous interrogation of Src kinase signaling and tubulin cytoskeleton disruption. This is particularly valuable in distinguishing direct effects on proliferation from cytoskeletal-dependent processes in cancer research.
    • Anticancer Agent Targeting Src Kinase: In studies of triple-negative breast cancer and prostate cancer models, KX2-391 demonstrated low-nanomolar IC50 values for Src inhibition and potent antiproliferative effects, often outperforming ATP-competitive Src inhibitors due to its unique binding mode (article 3).
    • HBV Replication Pathway Interference: The reference study (Harada et al., 2017) revealed that KX2-391 suppresses HBV transcription by targeting the precore promoter, independent of the HBV X protein. Notably, its effect is mediated by tubulin polymerization inhibition rather than Src blockade, highlighting its role as a pathway-selective antiviral agent. This complements findings in article 1, which elaborates on how KX2-391’s pathway specificity facilitates mechanistic clarity in HBV and cancer models.
    • BoNT/A Inhibition: By targeting the BoNT/A light chain, KX2-391 blocks SNAP-25 cleavage at 10–40 μM, presenting a novel angle for neurotoxin research and potential therapeutic exploration, as discussed in article 2.
    • Clinical Relevance: KX2-391’s use as a topical 1% ointment for actinic keratosis and oral agent (40–120 mg/day) in tumor studies demonstrates its translational value. Achievable plasma concentrations mirror those used in preclinical workflows, facilitating direct bench-to-bedside translation.
    • Compatibility with High-Content and High-Throughput Platforms: As highlighted in article 4, the compound’s robust potency and solubility make it suitable for automated screening, multi-parameter imaging, and multiplexed endpoint analyses.

    Collectively, these features distinguish KX2-391 dihydrochloride as a versatile, data-driven, and reproducible research tool, validated for both pathway elucidation and translational investigation.

    Troubleshooting and Optimization Tips

    • Solubility: KX2-391 dihydrochloride is insoluble in water but dissolves readily in DMSO and ethanol. To avoid precipitation in cell culture, limit DMSO to ≤0.5% final concentration. For higher concentrations, pre-warm ethanol stocks and mix thoroughly before dilution.
    • Compound Degradation: Store at -20°C in desiccated, light-protected conditions. Avoid repeated freeze-thaw cycles by aliquoting stock solutions.
    • Cellular Uptake: If variable activity is observed, verify compound delivery (e.g., via LC-MS/MS or fluorescence labeling) and confirm that serum proteins do not sequester the molecule. Consider serum-free pre-incubation for sensitive assays.
    • Off-Target Effects: Use orthogonal controls (e.g., siRNA for Src, classic tubulin inhibitors like nocodazole) to confirm pathway-specific actions, since KX2-391’s dual targeting can yield overlapping phenotypes.
    • Assay Sensitivity: For HBV transcription studies, optimize infection multiplicity and ensure NanoLuc or qPCR readouts are in the linear range. In BoNT/A assays, titrate both toxin and inhibitor carefully to detect partial inhibition.
    • Batch-to-Batch Reproducibility: Source KX2-391 dihydrochloride from reputable vendors like APExBIO, which ensures research-grade purity and validated activity (article 5).

    Integrating these optimization tips, as outlined in the workflow-focused article 4, improves reproducibility and minimizes experimental variability.

    Future Outlook: Expanding the Impact of KX2-391 Dihydrochloride

    The versatility of KX2-391 dihydrochloride positions it at the forefront of research on cancer, chronic viral infections, and neurotoxin countermeasures. Ongoing developments include:

    • Precision Oncology: Integration with personalized medicine approaches to target Src-dependent and cytoskeleton-driven tumors, leveraging its lack of significant peripheral neuropathy for safer combinatorial regimens.
    • Next-Generation Antiviral Therapies: Building on its ability to selectively suppress HBV transcription at the precore promoter, future studies may evaluate synergy with nucleos(t)ide analogs or gene-editing strategies to eradicate HBV cccDNA reservoirs, as suggested by Harada et al., 2017.
    • Neurotoxin Research: Further mechanistic studies on BoNT/A inhibition could inform therapeutic interventions for toxin exposure or synaptic disorders.
    • Expanding Pathway Profiling: High-content screening platforms will benefit from KX2-391’s dual action for dissecting pathway crosstalk and compensatory signaling in drug-resistant models.

    As demonstrated across referenced studies, KX2-391 dihydrochloride (SKU: A3535) from APExBIO remains a trusted, high-performance solution for scientists seeking to probe complex signaling dynamics or advance translational therapeutics. Its dual mechanism, exceptional potency, and robust clinical foundation continue to inspire new applications and innovations in biomedical research.